998P - An optimal cumulative dose of cisplatin in chemoradiotherapy as a definitive treatment for non-metastatic nasopharyngeal carcinoma: a retrospective...

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Head and Neck Cancers
Surgical oncology
Therapy
Radiation oncology
Presenter Pongwut Danchaivijitr
Citation Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376
Authors P. Danchaivijitr1, N. Ngamphaiboon2, C. Jiarpinitnun3, E. Sirachainan4, P. Pattaranutaporn3, J. Setakornnukul5
  • 1Medical Oncology Division, Department Of Medicine, Siriraj Hospital, Mahidol University, 10700 - Bangkok/TH
  • 2Division Of Medical Oncology, Department Of Medicine, Ramathibodi Hospital, 10400 - Bangkok/TH
  • 3Radiation Oncology, Ramathibodi Hospital, 10400 - Bangkok/TH
  • 4Medicine, Ramathibodi Hospital, 10400 - Bangkok/TH
  • 5Radiation Oncology, Siriraj Hospital, Mahidol University, 10700 - Bangkok/TH

Abstract

Background

To date, there is no recommended optimal cumulative dose (OCD) of cisplatin in definitive chemoradiotherapy (CRT) for non-metastatic nasopharyngeal carcinoma (NPC). We conducted a retrospective study to determine a MCCD in NPC treated with CRT.

Methods

Histologically confirmed non-metastatic NPC patients treated at the Ramathibodi and Siriraj Hospitals between 2007 and 2015 were identified. Baseline patient characteristics, treatment modality and survivals were abstracted. The OCD of cisplatin >200 mg/m2 was used as a stratification dose level. Primary end point was 3-year survival (OS). The Kaplan-Meier with log-rank test were used for analysis. A p-value

Results

Total of 289 NPC patients were included for analysis. Two hundred and thirty one patients received OCD of cisplatin >200 mg/m2, while 58 patients did not. Median age was 52 (range 17-75). Median radiation dose was 6996 cGY (range 1440-7840). Median cisplatin dose was 240 mg/m2 (range 75-361). There was no statistical difference in demographics between these 2 groups, except radiation interruption was more common in patients who received ODC of cisplatin >200 mg/m2 (27% vs 3%, p 

Conclusions

Our study demonstrated no significant difference in 3 year OS and DFS between OCD of cisplatin greater or lesser than 200 mg/m2. A prospective study comparing standard vs lower dose of cisplatin is warranted to minimize cisplatin related toxicity during chemoradiotherapy for NPC.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.